IGF-I bioavailability in congenital isolated growth hormone deficiency
Authors' conclusion
Our findings suggest altered IGF-I bioavailability regulation via the ISPa in congenital lifetime GHD, leading to increased PAPP-A2 proteolytic activity, reduced PAPP-A enzymatic activity, and reduced sequestration of PAPP-A2 by STC2.
Study context
- Population
- Itabaianinha cohort, Brazil: congenital isolated GH deficiency (GHD) due to homozygous GHRH-R gene mutation, heterozygotes and wild-type controls
- Exposure
- GHD vs heterozygotes (HTZ) vs HMZ
- Outcome
- IGFBP 4-STC2-PAPP-A axis (ISPa) parameters
Methodological detailsISPa parameters measured at LMU Klinikum, Munich; other biochemistry at Federal University of Sergipe, Brazil
- ISPa parameters measured at LMU Klinikum, Munich; other biochemistry at Federal University of Sergipe, Brazil
Main finding
As reported in the abstract
- STC2, Pregnancy-associated plasma protein A (PAPP-A) and PAPP-A-STC2 complex did not differ between groups
- PAPP-A2 and intact IGFBP 4 higher in GHD
- GHD vs HMZ: P < 0.05
- GHD vs HMZ: P < 0.01
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| GH, IGF-I, IGF-II, free IGF-I and IGFBP 3GHD vs HMZ · markedly low in GHD | P < 0.001 |
GH, IGF-I, IGF-II, free IGF-I and IGFBP 3
- HTZ resembled HMZ
Correlations
- IGF-I and IGFBP 3 positively correlated with IGF-II; intact IGFBP 4 and PAPP-A2 inversely correlated with IGF-I and IGF-II
Original publication
IGF-I bioavailability in congenital isolated growth hormone deficiency. Eur J Endocrinol. Published 13 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →